Article Text

Download PDFPDF

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
  1. Margaret K Callahan1,
  2. Christine E Horak2,
  3. Michael A Curran1,
  4. Travis Hollman1,
  5. David A Schaer1,
  6. Jianda Yuan1,
  7. Alexander M Lesokhin1,
  8. Shigehisa Kitano1,
  9. Quan Hong2,
  10. Charlotte E Ariyan1,
  11. Klaus J Busam1,
  12. William Feely2,
  13. Maria Jure-Kunkel2,
  14. Joseph Grosso2,
  15. Jason S Simon2,
  16. Alan J Korman3,
  17. Jon M Wigginton2,
  18. Ashok K Gupta2,
  19. Xiaoling Zhang4,
  20. Therese Phillips4,
  21. Pauline Simmons4,
  22. Mario Sznol5 and
  23. Jedd D Wolchok1
  1. Aff1 grid.51462.340000000121719952Memorial Sloan-Kettering Cancer Center New York NY USA
  2. Aff2 grid.419971.3Bristol-Myers Squibb Princeton NJ USA
  3. Aff3 grid.419971.3Bristol-Myers Squibb Redwood City CA USA
  4. Aff4 Dako North America, Inc. Carpinteria CA USA
  5. Aff5 grid.47100.320000000419368710Yale University New Haven CT USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptors are immune checkpoint receptors involved in tumor immune evasion. Nivolumab and ipilimumab are fully human monoclonal PD-1 and CTLA-4 blocking antibodies, respectively, and have shown clinical antitumor activity as monotherapy. In a multicohort, phase 1 study with melanoma patients (pts), nivolumab/ipilimumab combination produced objective response rates (ORRs) of up to 53% (NCT01024231). We evaluated putative predictive biomarkers for nivolumab and ipilimumab monotherapy in the combination setting, including tumor PD-L1 expression, absolute lymphocyte count (ALC), peripheral blood (PB) myeloid-derived suppressor cells (MDSCs), and pharmacodynamic changes in T-cell phenotype.


An automated immunohistochemistry assay (developed by Dako) using the 28-8 PD-L1 antibody was used to evaluate tumor PD-L1 membrane expression in archival FFPE specimens. ALC was measured in serial PB samples. Flow cytometry was used to characterize changes in percentage, number, and phenotype of activated CD4+ and CD8+ T cells and MDSC.


Using a cut-off of 5% tumor cell membrane staining, 37% of pts (13/35) exhibited PD-L1 expression. Nine of 22 pts (41%) with PD-L1 negative tumors and 6/13 pts (46%) with PD-L1 positive tumors achieved an OR. ALC increase vs baseline was not observed, but phenotypic changes in PB T-cell subsets (increases in percentage of CD4 and CD8 expressing HLA-DR, ICOS, and/or Ki67) were evident. Six of 14 pts (43%) with low ALC (<1.0 at wk 6-7) achieved an OR, vs 15/38 pts (39%) with ALC ≥1.0 at wk 6-7. Lower pretreatment percent MDSC correlated with higher ORR (P<0.05).


ORRs with nivolumab/ipilimumab combination in this small pt subset were not associated with PD-L1 expression or ALC, in contrast to prior observations with nivolumab or ipilimumab monotherapy, respectively. Compared with either therapy alone, the combination may induce an immune response with distinct characteristics. PB and tumor biomarkers, and their relationship to clinical activity patterns, will be further investigated in this study and in phase 2/3 randomized studies.